GLP-1 & compounded medication availability in Montana (2026)

Montana has the most unusual backdrop of any state on this page: its Right to Try Act reaches further than any other state’s experimental-access law, which has made the state a magnet for longevity-clinic headlines. Almost none of that touches a compounded prescription arriving by mail. That follows the board’s ordinary registration rules and the state’s telehealth law, both cited below. Eight of our ten lines ship to Montana; two do not, and we say so.

Baseline state

Availability facts last reviewed: November 16, 2026

What ships to Montana: the full ten

Availability of all ten OrderlyMeds product lines in Montana, with typical delivery times and notes
Product lineAvailable in Montana?Typical deliveryNotes
GLP-1 (compounded semaglutide) Yes 8–10 business days Shipped by registered out-of-state mail-service partner pharmacies.
GLP-1/GIP (compounded tirzepatide) Yes 8–10 business days National flat pricing; Montana adds nothing.
NAD+ Yes 8–10 business days Ordered through the usual telehealth evaluation.
Sermorelin Yes 8–10 business days Fulfilled by board-registered partner pharmacies.
Glutathione No N/A Not part of the OrderlyMeds catalog yet.
BPC-157 Yes 8–10 business days Compounded injectable; cited record directly below.
TB-500 Yes 8–10 business days Compounded injectable; see the cited section beneath.
KPV No N/A Dispensed nowhere by OrderlyMeds, because it is not an injectable line.
Epitalon Yes 8–10 business days Compounded injectable; citations below.
MOTS-c Yes 8–10 business days Compounded injectable; carries its own federal record, below.

Last reviewed November 16, 2026. Montana’s experimental-access regime, cited in the regulator section, moves no row in this table in either direction.

Research peptides in Montana, minus the mythology

Montana’s reputation invites confusion here, so the catalog facts first: OrderlyMeds dispenses BPC-157, TB-500, Epitalon and MOTS-c to Montana as compounded injectables on patient-specific prescriptions, through the same pharmacy registration path as any state, owing nothing to Montana’s experimental-access laws. KPV is in the formulary nowhere. Each section below cites its one substance’s federal record: FDA’s safety position and the compounding pathway now covering it, stated identically for shipped and unshipped lines alike.

BPC-157 in Montana

Montana orders for BPC-157 are filled as a compounded injectable, on a patient-specific prescription, by the ordinary pharmacy path rather than the experimental-clinic one.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

TB-500 in Montana

TB-500 is dispensed to Montana addresses as a compounded injectable, on a patient-specific prescription.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

KPV in Montana

KPV is not dispensed by OrderlyMeds in Montana or anywhere, because our peptide lines are injectables, which KPV is not.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

Epitalon in Montana

Epitalon ships to Montana as a compounded injectable.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

MOTS-c in Montana

MOTS-c is dispensed to Montana as a compounded injectable; the record below is specific to MOTS-c.

FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.

What Montana’s pharmacy regulators say about compounded medications

Helena’s pharmacy paperwork is plainer than the state’s reputation. The board registers out-of-state mail-service pharmacies, the registration names a pharmacist-in-charge in the pharmacy’s home state, and the telehealth authorization is general-purpose. The famous part, the nation’s broadest experimental-treatment access regime, is a clinic-based framework inside Montana, and the final citation below is here to mark the boundary between that regime and an ordinary compounded prescription.

Montana’s Board of Pharmacy licenses and regulates pharmacies under Title 37, ch. 7, MCA and its administrative rules; it has published no GLP-1-specific or peptide-specific restriction. Source: Montana Board of Pharmacy.

Each out-of-state mail service pharmacy shipping prescriptions to Montana patients must be registered with the Board of Pharmacy, providing ownership information and the identity of a pharmacist-in-charge licensed in the pharmacy’s home state (MCA 37-7-703). Source: MCA 37-7-703 — Registration requirements.

Montana authorizes any licensed health care provider to deliver services by telehealth when telehealth is appropriate for the service and meets the in-person standard of care (MCA 37-2-305). Source: MCA 37-2-305 — Telehealth services.

Montana’s Right to Try Act (MCA Title 50, ch. 12) separately permits eligible patients to access experimental treatments through providers inside the state — a clinic-based regime distinct from pharmacy compounding that neither expands nor limits how a mail-order compounded prescription is filled. Source: MCA Title 50, ch. 12 — Right to Try Act.

So an order to Billings or Missoula takes the ordinary national route: online eligibility, a telehealth evaluation with a provider authorized for Montana, a patient-specific prescription, fulfillment by a registered mail-service partner pharmacy, and tracked delivery inside the published 8–10 business-day window, at the same flat national price, with no Montana-only paperwork on the patient’s side.

Montana availability FAQs

Can I get compounded semaglutide in Montana?

Yes. Compounded semaglutide and compounded tirzepatide both ship to Montana addresses, from $74/month for new semaglutide customers in their first two months.

Does Montana’s Right to Try law change what OrderlyMeds can ship?

No. That regime covers experimental care through providers inside Montana. An OrderlyMeds order is a compounded prescription filled by a registered pharmacy. The regulator section above cites both frameworks and the boundary between them.

Which research peptides ship to Montana?

BPC-157, TB-500, Epitalon and MOTS-c, each as a compounded injectable on a patient-specific prescription. KPV is not in the formulary in any state. Every section above carries its substance’s own cited federal record.

What is the delivery window for Montana?

The published window is 8–10 business days from signup, with tracking throughout.

Keep exploring

Ready when you are

See if you’re eligible

Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.

Check eligibility

Secure. Private. No commitment

The OrderlyMeds eligibility check on a phone